Petlife Pharmaceuticals, Inc. (PTLF)
Petlife Pharmaceuticals, Inc. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Los Angeles, CA, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $19,675. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of 0.0%. Its beta of 3.91 implies it has historically moved more than the broad market.
Based in Los Angeles, California, Petlife Pharmaceuticals, Inc. is dedicated to the discovery, formulation, commercialization, and ongoing support of both medicinal drugs and nutritional supplements for pets. Their primary focus is on addressing canine and feline cancer and various autoimmune conditions, such as arthritis, within the United States market. The company's leading product is Vitalzul, which functions by obstructing the formation of new blood vessels crucial for the growth of solid tumors. Petlife is also progressing the development of Vitalzul into a potent, prescription-only oral medication, as well as a highly concentrated version for direct intravenous or injectable application to tumors. Additionally, their offerings extend to developing palatable treats suitable for dogs and cats.
Petlife Pharmaceuticals, Inc. is most often compared with the following Healthcare names: